Biomarin Pharm patents expiration
1. Kuvan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months from now) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(6 months from now) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(6 months from now) | |
| US7947681 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(6 months from now) | |
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(6 months from now) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months from now) | |
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months from now) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(6 months from now) | |
|
US7566714 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 19 days from now) | |
|
US7947681 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(1 year, 19 days from now) | |
|
US7612073 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(1 year, 19 days from now) | |
|
US7727987 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(1 year, 19 days from now) | |
|
US8067416 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 19 days from now) | |
|
US8318745 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(1 year, 19 days from now) | |
|
USRE43797 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
May, 2025
(1 year, 19 days from now) | |
|
US9433624 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 19 days from now) | |
| US8003126 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(1 year, 6 months from now) | |
| US7566462 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(1 year, 6 months from now) | |
|
US7566462 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(2 years from now) | |
|
US8003126 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(2 years from now) | |
| US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(8 years from now) | |
|
US9216178 (Pediatric) | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(9 years from now) | |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; T...
Dosage: POWDER;ORAL; TABLET;ORAL
KUVAN family patents
2. Voxzogo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(6 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
VOXZOGO family patents